NHE3 Regulation and Signaling Complexes
NHE3 调节和信号传导复合物
基本信息
- 批准号:8277967
- 负责人:
- 金额:$ 54.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-04-01 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAbbreviationsAcuteAffectAreaBindingBinding ProteinsBiological AssayBrush BorderC-terminalCa(2+)-Calmodulin Dependent Protein KinaseCaco-2 CellsCell LineClathrinComplexDetergentsDevelopmentDiseaseDominant-Negative MutationEndocytosisEpithelialGoalsGrantHealthImmunoblottingIntestinesKnockout MiceLeadLipid BindingLipidsLiposomesMeasurementMembraneMembrane MicrodomainsMicroscopyMotorMutagenesisN-terminalPDPK1 genePharmacotherapyPhosphatidylinositol 4,5-DiphosphatePhosphatidylinositolsPreparationPrincipal InvestigatorProteinsRecruitment ActivityRegulationRoleSHPS-1 proteinSignal TransductionSignaling MoleculeSystemTestingViral Vectorabsorptionantiporterbasecalmodulin-dependent protein kinase IIcasein kinase IIcellular microvilluscoated pitezringenetic regulatory proteinimprovedinsightmouse modelmutantmyosin VIphosphoinositide-3,4,5-triphosphateprogramsscaffoldsmall hairpin RNAsodium-hydrogen exchanger regulatory factortraffickingtwo-photon
项目摘要
This proposal is to test the hypothesis that NHE3, the epithelial brush border Na/H antiporter, undergoes
acute regulation by acting as a scaffold for some of its regulatory proteins and that the assembled regulatory
complexes form in highly organized domains of the NHE3 C-terminus. The long-term goal is to understand how
intestinal Na absorption is regulated as necessary background for developing drug therapy for diarrheal
diseases based on the goal of pharmacologically stimulating NHE3 activity. The hypothesis underlying this
grant will be tested by study of NHE3 regulation which centers on its C-terminal domain between aa 475 and
585, which is close to the N-terminal transport domain, and emphasizes the role of direct ezrin binding to
NHE3, which was identified during the previous grant period as being necessary for multiple aspects of
trafficking of NHE3. The Specific Aims of this grant are: Aim I: To understand how the C-terminal domain to
which ezrin directly binds is involved in regulation NHE3 activity. We propose to define the role of direct ezrin
binding to NHE3 on acute stimulation and inhibition of NHE3. We have identified that the domain of NHE3
which directly binds ezrin also interacts with multiple components of the PI-3K system and we will use
mutagenesis to identify the role of each component on NHE3 activity. We will test the hypothesis that NHE3
trafficking is dependent on binding to the motor protein myosin VI. Aim II: We have identified that the
phosphoinositides PIP2 and PIP3 appear to directly bind to NHE3 between aa 475 and 585. We will use
mutagenesis and liposomal pull down assays to identify the domains of the NHE3 C-terminus through which
interactions with the phosphoinositides occur and determine their role in NHE3 trafficking and basal and
regulated activity. Studies will be carried out mostly in the polarized intestinal Na absorptive cell line, Caco-2
cells using mutagenesis, shRNA and dominant-negative constructs transiently infected via viral vectors,
supplemented with commercially available knockout mice models of some of the NHE3 associating proteins
with consequences determined using two-photon microscopy/SNARF-4F measurement of NHE3 activity in
intact intestine.
该提议是为了检验以下假设:上皮刷边界Na/h抗植物的NHE3经历了
通过充当某些调节蛋白的脚手架来调节急性调节,并组装了调节
在NHE3 C末端高度组织的结构域中形成复合物。长期目标是了解如何
肠道NA的吸收是开发腹泻药物治疗的必要背景
基于药理学刺激NHE3活性的疾病。这是基础的假设
赠款将通过研究NHE3法规的研究,该法规以其C末端域为中心,在AA 475和
585,靠近N末端运输结构域,并强调直接Ezrin结合与
NHE3,在上一个赠款期间被确定为对于多个方面所必需的
NHE3的贩运。这笔赠款的具体目的是:目标I:了解C端领域如何
Ezrin直接结合的是调节NHE3活性。我们建议定义直接Ezrin的作用
在急性刺激和抑制NHE3时与NHE3结合。我们已经确定了NHE3的域
直接结合Ezrin也与PI-3K系统的多个组件相互作用,我们将使用
诱变以识别每个成分在NHE3活性中的作用。我们将测试NHE3的假设
运输取决于与运动蛋白肌球蛋白VI的结合。 AIM II:我们已经确定
磷酸肌醇PIP2和PIP3似乎直接与AA 475和585之间的NHE3结合。我们将使用
诱变和脂质体下拉测定法,以识别NHE3 C末端的域
与磷酸肌醇的相互作用发生并确定其在NHE3运输和基础上的作用
受调节活动。研究将主要在偏振肠吸收细胞系Caco-2中进行
细胞使用诱变,shRNA和显性阴性构建体瞬时通过病毒载体感染,
补充一些NHE3蛋白的市售敲除小鼠模型
使用两光子显微镜/SNARF-4F测量NHE3活性的后果
完整的肠。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK DONOWITZ其他文献
MARK DONOWITZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK DONOWITZ', 18)}}的其他基金
Mechanisms and Correction of Abnormal Bicarbonate Secretion by DRA in Diarrhea
DRA 治疗腹泻时碳酸氢盐异常分泌的机制及纠正
- 批准号:
9753444 - 财政年份:2019
- 资助金额:
$ 54.47万 - 项目类别:
Translational Approaches to Develop Drug Therapy for Diarrhea
开发腹泻药物治疗的转化方法
- 批准号:
9892562 - 财政年份:2019
- 资助金额:
$ 54.47万 - 项目类别:
Mechanisms and Correction of Abnormal Bicarbonate Secretion by DRA in Diarrhea
DRA 治疗腹泻时碳酸氢盐异常分泌的机制及纠正
- 批准号:
9981963 - 财政年份:2019
- 资助金额:
$ 54.47万 - 项目类别:
Pathogenesis of E. coli and Shigella infections in human enteroid models
人肠模型中大肠杆菌和志贺氏菌感染的发病机制
- 批准号:
10190298 - 财政年份:2016
- 资助金额:
$ 54.47万 - 项目类别:
Pathogenesis of E. coli and Shigella infections in human enteroid models
人肠模型中大肠杆菌和志贺氏菌感染的发病机制
- 批准号:
9982173 - 财政年份:2016
- 资助金额:
$ 54.47万 - 项目类别:
Pathogenesis of E. coli and Shigella infections in human enteroid models
人肠模型中大肠杆菌和志贺氏菌感染的发病机制
- 批准号:
10745560 - 财政年份:2016
- 资助金额:
$ 54.47万 - 项目类别:
Pathogenesis of E. coli and Shigella infections in human enteroid models
人肠模型中大肠杆菌和志贺氏菌感染的发病机制
- 批准号:
10427388 - 财政年份:2016
- 资助金额:
$ 54.47万 - 项目类别:
Translational Approaches to Develop Drug Therapy for Diarrhea
开发腹泻药物治疗的转化方法
- 批准号:
9298626 - 财政年份:2014
- 资助金额:
$ 54.47万 - 项目类别:
Translational Approaches to Develop Drug Therapy for Diarrhea
开发腹泻药物治疗的转化方法
- 批准号:
8769280 - 财政年份:2014
- 资助金额:
$ 54.47万 - 项目类别:
Human Intestinal Organoids: Pre-Clinical Models of Non-Inflammatory Diarrhea
人类肠道类器官:非炎症性腹泻的临床前模型
- 批准号:
8668192 - 财政年份:2012
- 资助金额:
$ 54.47万 - 项目类别:
相似海外基金
The Na/K-ATPase receptor function as a novel therapeutic target in myocardial infarction
Na/K-ATP酶受体作为心肌梗死的新型治疗靶点
- 批准号:
9813314 - 财政年份:2019
- 资助金额:
$ 54.47万 - 项目类别:
Innate immunity and cardiovascular function in sepsis
脓毒症的先天免疫和心血管功能
- 批准号:
8307963 - 财政年份:2009
- 资助金额:
$ 54.47万 - 项目类别:
Innate immunity and cardiovascular function in sepsis
脓毒症的先天免疫和心血管功能
- 批准号:
7901577 - 财政年份:2009
- 资助金额:
$ 54.47万 - 项目类别:
Innate immunity and cardiovascular function in sepsis
脓毒症的先天免疫和心血管功能
- 批准号:
8118998 - 财政年份:2009
- 资助金额:
$ 54.47万 - 项目类别: